Drug compositions comprising an anti-parasitic and proton pump inhibitor
Inventors
Sutherland, David Clayton • Zorn, James Kyle • Carlo, Dennis J.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10137111-B2
Publication Date
2018-11-27
Expiration Date
Abstract
Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.
Core Innovation
The invention relates to pharmaceutical compositions and treatment methods for gastrointestinal conditions in a mammal. The compositions combine a proton pump inhibitor and an antiparasitic agent for oral administration, including non-solid oral formulations such as liquid or paste, and paste vehicles based on a melted polyethylene glycol base agent.
In one embodiment, the composition includes a paste formulated for oral administration to a mammal, comprising about 22% w/v omeprazole and about 30% w/v fenbendazole. A wetting agent is formulated in a melted polyethylene glycol base agent, and the paste may further include additional components such as carboxymethyl cellulose and buffers/preservatives.
The disclosure emphasizes reduction of gastrointestinal ulcer recovery/incidence time and improvement of ulcer grading outcomes, including prevention and no recurrence outcomes, in animal examples such as horses and camels. The compositions are also described in performance-related use, including for athletes, in connection with gastrointestinal ulcer prevention or improvement.
Claims Coverage
The partial claim set contains three independent claims that share a common core: an oral paste in a melted polyethylene glycol base vehicle, containing omeprazole and fenbendazole with a wetting agent. Additional excipient constraints are specified in certain independent claims.
Melted polyethylene glycol base paste with omeprazole and fenbendazole for oral administration to a mammal
A paste including about 22% w/v omeprazole, about 30% w/v fenbendazole, and a wetting agent formulated in a melted polyethylene glycol base agent for oral administration to a mammal.
Equine paste composition for oral syringe administration with omeprazole and fenbendazole
An equine composition including a paste including a melted polyethylene glycol base agent including 22% omeprazole, 30% fenbendazole, a wetting agent, and carboxymethyl cellulose formulated for administration from an oral syringe.
Melted polyethyleneglycol base paste including omeprazole, fenbendazole, carboxymethylcellulose, preservative, and wetting agent
A paste including about 22% w/v omeprazole, about 30% w/v fenbendazole, carboxymethylcellulose, a preservative, and a wetting agent formulated in a melted polyethyleneglycol base agent for oral administration to a mammal.
Across the independent claims, the main inventive coverage is an oral paste formulated in a melted polyethylene glycol base vehicle that contains specified amounts of omeprazole and fenbendazole, combined with a wetting agent. Additional coverage includes carboxymethyl cellulose and, in one independent claim, a preservative; one independent claim further specifies equine administration from an oral syringe.
Stated Advantages
Reduces gastrointestinal ulcer recovery/incidence time.
Reduces the required drug dose and side effects.
Improves ulcer grading outcomes, including prevention and no recurrence outcomes.
Documented Applications
Treatment of gastrointestinal conditions and gastrointestinal ulcer outcomes in horses and camels.
Prevention or improvement of gastrointestinal ulcer outcomes in athletes (performance-related use).
Interested in licensing this patent?